Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Ruxolitinib”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT03153982
What this trial is testing

Ruxolitinib in Operable Head and Neck Cancer

Who this might be right for
Head and Neck Squamous Cell Carcinoma
University of California, San Francisco 16
Testing effectiveness (Phase 2)Looking for participantsNCT05398809
What this trial is testing

Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata

Who this might be right for
Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced)Alopecia Areata
National Institute of Allergy and Infectious Diseases (NIAID) 70
Testing effectiveness (Phase 2)Looking for participantsNCT05980806
What this trial is testing

Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

Who this might be right for
MyelofibrosisModerate ThrombocytopeniaMild Thrombocytopenia
Karyopharm Therapeutics Inc 58
Testing effectiveness (Phase 2)Ended earlyNCT04366232
What this trial is testing

Efficacy of Intravenous Anakinra and Ruxolitinib During COVID-19 Inflammation

Who this might be right for
Covid-19
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer 2
Testing effectiveness (Phase 2)Study completedNCT03144687
What this trial is testing

Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis

Who this might be right for
MPN (Myeloproliferative Neoplasms)
Incyte Corporation 23
Testing effectiveness (Phase 2)Active Not RecruitingNCT02955940
What this trial is testing

An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib

Who this might be right for
Pancreatic CancerColorectal Cancer (CRC)Breast Cancer+1 more
Incyte Corporation 10
Testing effectiveness (Phase 2)Ended earlyNCT01251965
What this trial is testing

Phase l/II Study of Ruxolitinib for Acute Leukemia

Who this might be right for
Leukemia
M.D. Anderson Cancer Center 27
Testing effectiveness (Phase 2)Looking for participantsNCT07128381
What this trial is testing

Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)

Who this might be right for
Myelofibrosis (MF)Chronic Myelomonocytic Leukemia (CMML)
M.D. Anderson Cancer Center 66
Not applicableStudy completedNCT05853445
What this trial is testing

A Prospective, Non-interventional Study of JAKAVI® (Ruxolitinib) Treatment in Patients With Polycythemia Vera

Who this might be right for
Polycythemia Vera
Novartis Pharmaceuticals 467
Testing effectiveness (Phase 2)Study completedNCT02041429
What this trial is testing

Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca

Who this might be right for
Recurrent Breast CancerMetastatic Breast Cancer
Dana-Farber Cancer Institute 20
Large-scale testing (Phase 3)Active Not RecruitingNCT06959225
What this trial is testing

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)

Who this might be right for
Hidradenitis Suppurativa
Incyte Corporation 580
Testing effectiveness (Phase 2)UnknownNCT06304025
What this trial is testing

Sequential Administration of WJ-MSCs for the Treatment of GvHD Refractory to Second Line Treatment

Who this might be right for
Graft Versus Host Disease
Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle 10
Not applicableNo Longer AvailableNCT01730755
What this trial is testing

Ruxolitinib for Chuvash Polycythemia

Who this might be right for
Erythrocytosis, Familial, 2
Washington University School of Medicine
Not applicableWithdrawnNCT03274778
What this trial is testing

Effect of Ruxolitinib on Tumor Infiltrating Myeloid Cells

Who this might be right for
Prostate Cancer
Oncology Institute of Southern Switzerland
Large-scale testing (Phase 3)Looking for participantsNCT07357727
What this trial is testing

Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

Who this might be right for
Primary Myelofibrosis (PMF)Post-polycythemia Vera Myelofibrosis (PPV-MF)Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Novartis Pharmaceuticals 460
Testing effectiveness (Phase 2)Active Not RecruitingNCT03669965
What this trial is testing

KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera

Who this might be right for
Polycythemia Vera
Kartos Therapeutics, Inc. 20
Post-approval studies (Phase 4)Study completedNCT01558739
What this trial is testing

Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)

Who this might be right for
Primary Myelofibrosis (PMF)Post Polycythaemia Myelofibrosis (PPV MF)Post Essential Thrombocythaemia Myelofibrosis (PET-MF)
Novartis Pharmaceuticals 48
Large-scale testing (Phase 3)Study completedNCT02038036
What this trial is testing

Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.

Who this might be right for
Polycythemia Vera
Novartis Pharmaceuticals 149
Testing effectiveness (Phase 2)Study completedNCT02066532
What this trial is testing

Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer

Who this might be right for
Metastatic Breast CancerBreast CarcinomaHER-2 Positive Breast Cancer
Dawn L. Hershman 32
Very early researchLooking for participantsNCT04744116
What this trial is testing

Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease

Who this might be right for
Hematopoietic and Lymphoid Cell NeoplasmSteroid Refractory Graft Versus Host Disease
M.D. Anderson Cancer Center 24
Next Page